Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1Phase 1/2 1

Status

Completed 22Recruiting 12Active not recruiting 10Withdrawn 5Terminated 3Unknown 2Suspended 1

Sponsor Class

INDUSTRY 3OTHER 1NETWORK 1

Study Type

Interventional 5

Sponsor

Cancer Type

Head & Neck 4Tumor-Agnostic 1

Conditions

Carcinoma, Non-Small-Cell Lung 23Squamous Cell Carcinoma of Head and Neck 14Head and Neck Neoplasms 12Lung Neoplasms 10Uterine Cervical Neoplasms 9Neoplasms 9Cholangiocarcinoma 5Carcinoma, Squamous Cell 5Carcinoma 5Mesothelioma, Malignant 4Carcinoma, Hepatocellular 4Tongue Neoplasms 3Small Cell Lung Carcinoma 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Pancreatic Neoplasms 3Oropharyngeal Neoplasms 3Mouth Neoplasms 3Laryngeal Neoplasms 3Hypopharyngeal Neoplasms 3Breast Neoplasms 3Biliary Tract Neoplasms 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Ovarian Neoplasms 2Nasopharyngeal Neoplasms 2Mesothelioma 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Esophageal Squamous Cell Carcinoma 2Esophageal Neoplasms 2

Interventions

Cisplatin 5nimotuzumab 2X-Rays 2Radiotherapy 2Magnetic Resonance Spectroscopy 2trifluridine tipiracil drug combination 1sargramostim 1palladium-bacteriopheophorbide 1padeliporfin 1imgatuzumab 1galactomannan 1futuximab 1fluoromisonidazole 1capmatinib 1cabozantinib 1Tomography, Optical Coherence 1Standard of Care 1Specimen Handling 1Ramucirumab 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Image-Guided 1Practice Guidelines as Topic 1Platinum 1Nivolumab 1N-benzhydryl-5-(2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo(1,2-a)(1,5)diazocine-8-carboxamide 1Mitomycin 1LMB-100 1Ipilimumab 1Interviews as Topic 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Withdrawn × Carcinoma × Cisplatin × Clear all
NCT01345084 2025-03-28

NICAP

Eurofarma Laboratorios S.A.

Phase 3 Withdrawn
Head & Neck

Carcinoma, Head and Neck Neoplasms

NCT06084845 2024-07-25

Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer

Eastern Cooperative Oncology Group

Phase 2 Withdrawn
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms

NCT02624999 2020-01-22

Study Comparing AlloVaxâ„¢ to Chemotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head & Neck

Mirror Biologics, Inc.

Phase 2 Withdrawn
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Head and Neck Neoplasms

NCT02298595 2017-11-13

Cetuximab, Cisplatin and BYL719 for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

University of Pittsburgh

Phase 1/2 Withdrawn
Head & Neck

Carcinoma, Carcinoma, Squamous Cell, Oropharyngeal Neoplasms

NCT01301612 2014-07-14

Study of Nimotuzumab, Radiation Therapy and Cisplatin Versus Radiation Therapy and Cisplatin for Treatment of Stage IB e IVA UCC(CORUS)

Eurofarma Laboratorios S.A.

Phase 2 Withdrawn
Tumor-Agnostic

Adenocarcinoma, Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡